Please assess the completion status of the following clinical trial:

Trial Title: LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Female patients \>=18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer~2. Stage IV metastatic disease~3. At least one measurable lesion according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1). Skin, bone and brain lesions are considered non-target lesions~4. Must have failed or progressed on either trastuzumab or lapatinib or trastuzumab and lapatinib treatment in the neoadjuvant and/or adjuvant setting~Exclusion criteria:~1. Prior first line therapy for metastatic breast cancer~2. Known pre-existing interstitial lung disease~3. Active brain metastases~4. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to trial treatment.~5. Cardiac left ventricular function with resting ejection fraction of less than 50%.~6. Prior treatment with Epidermal Growth Factor Receptor (EGFR)/HER2-targeted small molecules or antibodies other than trastuzumab and lapatinib in the neoadjuvant or adjuvant setting~7. Prior treatment with paclitaxel in the past 12 months~8. Must not have received prior vinorelbine treatment - Further exclusion criteria apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Afatinib 40mg once daily (OD) (Type: EXPERIMENTAL): Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
- Paclitaxel 80 mg/m2 weekly (Type: EXPERIMENTAL): Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
- Vinorelbine 25 mg/m2 weekly (Type: EXPERIMENTAL): Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).